Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05733689 · ClinicalTrials.gov registry record · Phase 1
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
A Phase 1 study of Gastroesophageal Adenocarcinoma, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05733689: Recruiting Phase 1 study of Gastroesophageal Adenocarcinoma, sponsored by University of California, Irvine.
NCT05733689 is a Phase 1 study of Gastroesophageal Adenocarcinoma that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 20 participants, below the 148-participant average among 8 other Gastroesophageal Adenocarcinoma trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05733689, a Phase 1 study of Gastroesophageal Adenocarcinoma, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 1b prospective, single arm, open-label trial determining the efficacy and feasibility of using a response-guided approach to help guide neoadjuvant chemotherapy in subjects with Stage IB, II or Stage III adenocarcinoma of the stomach or gastroesophageal junction (GEA).
Primary Outcome
Percent of patients who will undergo attempt at curative intent resection.
Conditions Studied
Interventions
- COMBINATION_PRODUCT FLOT
- COMBINATION_PRODUCT FOLFOX
- COMBINATION_PRODUCT FOLFIRI
- COMBINATION_PRODUCT FOLFIRINOX
- COMBINATION_PRODUCT PACLITAXEL with or without CARBOPLATIN
Study Locations (1)
California
- Chao Family Comprehensive Cancer Center, University - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-06-27 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
What NCT05733689 shows while recruiting
NCT05733689 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 148-participant average among 8 other Gastroesophageal Adenocarcinoma trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Gastroesophageal Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which FLOT is the first listed.
NCT05733689 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05733689 about?
NCT05733689 is a clinical study titled "Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)". This is a phase 1b prospective, single arm, open-label trial determining the efficacy and feasibility of using a response-guided approach to help guide neoadjuvant chemotherapy in subjects with Stage IB, II or Stage III adenocarcinoma of the stomach or gastroesophageal junction (GEA).
What is the current status of trial NCT05733689?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-06-27. Estimated completion is 2027-06.
What conditions does trial NCT05733689 study?
This clinical trial studies the following conditions: Gastroesophageal Adenocarcinoma.
What interventions are being tested in trial NCT05733689?
The interventions under investigation include: FLOT (COMBINATION_PRODUCT), FOLFOX (COMBINATION_PRODUCT), FOLFIRI (COMBINATION_PRODUCT), FOLFIRINOX (COMBINATION_PRODUCT), PACLITAXEL with or without CARBOPLATIN (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05733689?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05733689 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05733689's enrollment target sits among peer trials
20 9th of 8 the lowest of 8 other Gastroesophageal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastroesophageal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RECRUITING · Phase 1
-
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
RECRUITING · Phase 1
-
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
RECRUITING · Phase 1
-
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
ACTIVE NOT RECRUITING · Phase 1
-
A Study of a Personalized Neoantigen Cancer Vaccine
COMPLETED · Phase 1
-
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI